SOPHiA GENETICS SA (NASDAQ:SOPH) Given Consensus Rating of “Hold” by Brokerages

SOPHiA GENETICS SA (NASDAQ:SOPH) has been given a consensus rating of “Hold” by the five analysts that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $10.00.

A number of research firms recently issued reports on SOPH. BTIG Research increased their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. HC Wainwright boosted their target price on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Finally, Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st.

SOPHiA GENETICS Stock Performance

SOPH opened at $7.50 on Monday. The stock has a market capitalization of $629.17 million, a P/E ratio of -6.52 and a beta of 0.96. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58. SOPHiA GENETICS has a 12 month low of $3.10 and a 12 month high of $7.88. The firm’s fifty day simple moving average is $5.89 and its 200 day simple moving average is $5.22.

SOPHiA GENETICS (NASDAQ:SOPH) last released its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The firm had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. As a group, research analysts anticipate that SOPHiA GENETICS will post -0.77 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Jurgi Camblong sold 50,069 shares of the stock in a transaction on Friday, June 26th. The shares were sold at an average price of $5.80, for a total transaction of $290,400.20. Following the completion of the transaction, the chief executive officer owned 3,601,493 shares in the company, valued at approximately $20,888,659.40. This represents a 1.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ross Muken sold 9,838 shares of the firm’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $5.22, for a total transaction of $51,354.36. Following the completion of the transaction, the chief executive officer directly owned 670,651 shares of the company’s stock, valued at approximately $3,500,798.22. This trade represents a 1.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 318,592 shares of company stock worth $1,952,315. 4.88% of the stock is owned by insiders.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of large investors have recently modified their holdings of the business. AWM Investment Company Inc. acquired a new stake in shares of SOPHiA GENETICS in the second quarter valued at about $9,809,000. Hennion & Walsh Asset Management Inc. bought a new stake in SOPHiA GENETICS during the second quarter worth about $567,000. Royal Bank of Canada boosted its position in SOPHiA GENETICS by 3,130.2% during the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock valued at $96,000 after purchasing an additional 18,781 shares during the last quarter. Sei Investments Co. bought a new position in SOPHiA GENETICS in the first quarter valued at approximately $1,772,000. Finally, Principal Financial Group Inc. grew its stake in SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after purchasing an additional 9,800 shares in the last quarter. 31.59% of the stock is currently owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.